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OBJECTIVES: To estimate the ﬁnancial impact to the Ontario
Public Drug Programs (OPDP) for providing coverage for
methylnaltrexone subcutaneous injection (RELISTORTM) for the
treatment of Opioid Induced Constipation (OIC) in patients with
advanced illness, receiving palliative care when response to laxa-
tives has been insufﬁcient. METHODS: A population-based
model was developed to estimate the annual ﬁnancial impact of
adding methylnaltrexone to the OPDP drug formulary. Attrition
factors were applied in a stepwise approach starting with the
population of Ontario in order to forecast the number of pallia-
tive patients expected to use methylnaltrexone following its addi-
tion to the drug formulary. Targeted treatment population in the
analysis is limited to patients meeting the product monograph
indication/criteria. Only drug costs incurred by the OPDP are
included. No discounting or inﬂation were applied. Data sources
included literature sources, publicly available population statis-
tics, and market research. RESULTS: This analysis estimates that
funding methylnaltrexone, per product monograph indication,
in the province of Ontario would lead to an incremental drug
reimbursement cost of $1,754,265, $3,942,857, and $5,563,842
in Year 1, 2, and 3 respectively post listing. The total cumulative
impact, post listing over the three-year period is expected to be
$11.26 million. Pessimistic and optimistic scenarios were evalu-
ated in the sensitivity analysis to provide a range of costs to the
drug plan budget. The estimated impact over a three-year period
will be an incremental cost of $6.65 million and $17.46 million
for pessimistic and optimistic scenario respectively. CONCLU-
SIONS: Addition of methylnaltrexone will provide patients and
care providers with a therapeutic option to rapidly and reliably
improve patient well-being at the end-of-life while having a
modest impact on the OPDP drug budget.
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OBJECTIVES: A budget impact model was developed in order to
estimate the economic impact of increased pantoprazole intrave-
nous prescription in themanagement of Peptic Ulcer (PU) in Spain.
METHODS: The analytic model is based on data from disease
prevalence, population growth, drug consumption, ex-factory
prices andmarket shares forecasts for the Spanish market. It takes
the perspective of the Spanish National Health Care System and
time horizon considered is 5 years (annual discount rate at 5%).
Drugs considered in the study were intravenous proton-pump
inhibitors (PPIs): omeprazole, esomeprazole and pantoprazole.
The model estimates the annual cost to treat patients with PU
before and after of increased pantoprazol IV prescription. Annual
costs includes pharmacologic treatment, laboratory and diag-
nostic tests, specialist consultation, hospitalization and other
resources like transfusions, endoscopic treatments and surgery
interventions. Health care resource consumption and unit costs
have been obtained from a retrospective observational study that
evaluated the re-bleeding prevalence by PU in patients treatedwith
intravenous PPIs. All costs are referred to year 2007. RESULTS:
Target population with peptic ulcer in Spain would be around
362,193 in year 2007, arriving at 378,048 in 2012 due to increase
in Spanish population. Of these population it has been estimated
that 5092 patients in year 2007would be treatedwith intravenous
PIPs (5315 patients in year 2012). Directmedical costs for the next
5 years for PU was estimated at €78.5 million before the increased
pantoprazole prescription and at €77 million after its increase.
Mean cost per patient was estimated at 2,513€ before the in-
crease the pantoprazole participation and at 2464 after its
increase. CONCLUSIONS: This budget impact model estimates
that an increased intravenous pantoprazole prescription for the
treatment of PU in Spain is going to represent a net savings of €1.5
million in the Spanish Health Care System in the next ﬁve years.
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OBJECTIVES: To estimate the economic impact for the health
care system due to the substitution of intravenous omeprazole
and intravenous esomeprazole by intravenous pantoprazole in
the treatment of gastro oesophageal reﬂux disease in Spain.
METHODS: A budget impact model was developed. The ana-
lytic model was based on data from disease prevalence, popula-
tion growth, drug consumption, ex-factory prices and market
shares forecasts for Spain. It takes the perspective of the Spanish
National Health Care System and time horizon considered is ﬁve
years. Annual discount rate was set at 5%. Proton-pump inhibi-
tors (PPIs) are the drugs of choice for the treatment of gastro
oesophageal reﬂux disease (GERD) and drugs considered in the
study were omeprazole, esomeprazole and pantoprazole. The
model estimates the annual cost to treat patients with GERD
before and after the replacement by pantoprazol IV in the man-
agement of the disease in the Spanish setting. Annual costs
consist of pharmacologic treatments, laboratory and diagnostic
tests, specialist consultations, hospitalizations, transfusions,
endoscopic treatments and surgical interventions. All costs are
referred to 2007. RESULTS: It has been estimated that target
population with PPIs treatments for GERD in Spain would be
around 79,372 inhabitants in year 2007, arriving at 82,849 in
2012 due to Spanish population growth. Total cost for the next
5 years for the treatment of GERD with intravenous PIPs was
estimated at €1224 million before the substitution and at €1200
million after the substitution. Mean cost per patient was esti-
mated at €2513 before the replacement by intravenous panto-
prazole and at €2464 after its substitution. CONCLUSIONS:
This budget impact analysis estimates that increased pantopra-
zole intravenous prescription for the treatment of GERD in Spain
is likely to represent a net savings of €24 millions in the Spanish
National Health Care System in the next 5 years.
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OBJECTIVES: Alginates are often ﬁrst line therapy for patients
experiencing symptoms of gastro-oesophageal reﬂux (GORD).
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Several UK primary care organizations consider alginates to be
interchangeable and differentiate products solely on costs; as
such many have implemented alginate substitution programs.
The aim of this study was to evaluate the validity of alginate
substitution programs by conducting an economic evaluation of
the costs and outcomes of the two leading prescribed alginates in
the UK. METHODS: A decision-analytic model was constructed
based on cohort of 3367 patients starting alginate monotherapy
in primary care. Transition probabilities were derived from
observed switching patterns during the observation period. The
model was populated with previously reported health state utili-
ties to derive quality-adjusted life years (QALYs). Costs were
derived from treatment pathways examining 1st line of therapy /
initial therapy, and subsequent therapies (eg, 2nd line, 3rd line,
etc). Costs were calculated by summing all lines of treatment
prescribed over one year including the costs of clinical con-
sultations. The model calculated incremental cost-effectiveness
between GA and Peptac after 2 lines and 5 lines of therapy.
RESULTS: The average annual incremental cost difference
between patients starting monotherapy GA and Peptac after
2-lines and 5-lines of therapy was £2.04 and £3.06, respectively.
Disaggregation of costs indicated there was an increased propor-
tion of a cost attributed to consultation visits for those starting
on Peptac attributed to higher switching rates requiring a GP
consultation. The incremental cost per quality adjusted life year
for 2nd line and 5th line was £2887 and £5305 per QALY. In the
sensitivity analysis the model was insensitive to changes in QoL
scores attributed to failing therapy. The cost per QALY ﬁgures
were moderately inﬂuenced by the duration of treatment failure
before commencing 2nd line therapy. CONCLUSIONS: Based on
aggregated costs of therapy and reduced switching rates Gavis-
con Advance was cost-effective compared to Peptac. We suggest
that all alginates are clinically not the same and that a broader
range of costs and impact on patients should be taken into
consideration when implementing therapeutic substitution
programs.
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OBJECTIVES: Recent clinical trials have conﬁrmed that hepa-
titis C patients who failed to attain a sustained virologic
response (SVR) on interferon-based therapy (pegylated or non-
pegylated) may still attain SVR if they are re-treated with pegy-
lated interferon alfa 2b therapy in combination with ribavirin.
On the basis of the international EPIC trial, a license has been
granted for pegylated interferon alfa 2b and ribavirin to be
used in this type of re-treatment. We developed a cost-
effectiveness for this retreatment paradigm in Scotland, as part
of our manufacturer submission to the Scottish Medicines Con-
sortium. METHODS: Local costs were sourced and outcomes
data from the EPIC trial were applied. Utilities and disease pro-
gression parameters were sourced from widely published and
well-established sources including the British HTA report on
hepatitis C. Our base case cost-effectiveness model compared
the retreatment with no retreatment—this comparison reﬂects
the current available treatment options in Scotland. RESULTS:
Our base case model found retreatment with pegylated inter-
feron alfa 2b plus ribavirin to be a cost-effective therapy com-
pared with no retreatment. The ICER was £11,389/QALY in
the base case, however this cost-effectiveness measure varied
strongly by the genotype of the virus patients are carrying as
well as by the patient’s prior experience on therapy (i.e. why
they originally failed to attain SVR). Patients with less virulent
strains of hepatitis C and whose prior treatment failed due to
relapse or non-compliance represent the most cost-effective
subgroup with ICERs below £9000/QALY. CONCLUSIONS:
Aside from the differences in ICERs associated with the differ-
ent sub-groups identiﬁed, ICERs remained below the cost-
effectiveness threshold in the most typical treatment scenarios
suggesting that the therapy will be a cost-effective addition to
the Scottish treatment system.
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OBJECTIVES: Peptic ulcer bleeding (PUB) is a serious and life-
threatening condition. Currently, no proton pump inhibitor has a
label for being used in this setting. A recent multinational clinical
trial (ClinicalTrials.gov identiﬁer: NCT00251979) showed that
high-dose intravenous esomeprazole (HIE), when administered
after endoscopic haemostasis to patients with bleeding ulcers, is
effective in preventing re-bleeding. METHODS: A decision-tree
model was built, including patients with PUB following success-
ful endoscopic haemostasis performed within 24 hours of initial
presentation, comparing HIE (80 mg infusion, then 8 mg/h for 3
days) versus placebo, with both groups receiving oral esomepra-
zole 40 mg daily from days 4 to 30. The model adopted a 30-day
time horizon, using a Spanish third-party payer perspective. The
outcome was the rate of averted re-bleeds. Probabilities and
lengths of hospital stay were provided from the recent trial.
Hospital costs, including physician fees, and data for other
model assumptions were retrieved from the literature. RESULTS:
Re-bleed rates were 7.7% (n = 375) for HIE, and 13.6%
(n = 389) for the placebo group (p < 0.01). The average costs per
patient for the HIE and placebo strategies were €4924 and
€4994, respectively. Thus, HIE was the dominant strategy (both
more effective and less costly than placebo). Sensitivity analysis
conﬁrmed the robustness of the results, with the placebo strategy
being less expensive only under speciﬁc circumstances (eg. when
signiﬁcantly varying re-bleed rates or dropping the hospitaliza-
tion costs for patients with a re-bleed). CONCLUSIONS: Based
on recent high-quality clinical trial data and modelling, the high-
dose intravenous esomeprazole strategy was more effective and
less costly than the placebo strategy.
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